2024-03-28T10:53:32Z
https://nagoya.repo.nii.ac.jp/oai
oai:nagoya.repo.nii.ac.jp:00015512
2023-11-16T05:51:36Z
499:508:509:1466
Cisplatin, Etoposide, and Vincristine Combination Chemotherapy in the Treatment of Non-Small Cell Lung Cancer
WATANABE, ATSUSHI
98807
ICHIYAMA, SATOSHI
98808
SHIMOKATA, KAORU
98809
NAGURA, EIICHI
98810
SAITO, HIROSHI
98811
SAKA, HIDEO
98812
NOMURA, FUMIO
98813
SAKAI, SHUZO
98814
SAITO, HIDEHIKO
98815
Chemotherapy
Non-Small Cell Lung Cancer
Cisplatin
Etoposide
Vincristine
1993-03
Thirty patients with previously untreated, inoperable non-small cell lung cancer (NSCLC) were treated with cisplatin, etoposide and vincristine. Among twenty-nine evaluable patients, eight patients achieved partial response and the overall response rate was 28%. No patient achieved a complete response. The median survival time was 51 weeks. Myelosuppression was the dose-limiting toxicity. Four patients had a leukocyte nadir of less than l000/mm3, and one died from severe myelosuppression and sepsis. The other toxicities were nausea/vomiting, peripheral neuropathy, and alopecia. We conclude that cisplatin, etoposide, and vincristine combination chemotherapy offers moderate activity for inoperable non-small cell lung cancer.
departmental bulletin paper
Nagoya University School of Medicine
1993-03
Nagoya Journal of Medical Science
1-4
55
41
46
2186-3326
0027-7622
eng
http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/5514/5514.html